Ivermectin in the treatment of COVID-19-friend or foe?
dc.contributor.author | Schellack, Natalie | |
dc.contributor.author | Padayachee, N. | |
dc.contributor.author | Schellac, G. | |
dc.contributor.email | natalie.schellack@up.ac.za | en_US |
dc.date.accessioned | 2022-10-12T10:19:22Z | |
dc.date.available | 2022-10-12T10:19:22Z | |
dc.date.issued | 2021-03-10 | |
dc.description.abstract | The global number of deaths due to COVID-19 is almost at the two million mark, with over 35 000 deaths in South Africa. Although there are hopes of a safe and effective vaccination programme, the increasing number of COVID-19 cases in the country is putting a significant strain on the healthcare system. Ivermectin, an antiparasitic drug, has been widely published on social media platforms and news outlets as a socalled miracle drug for the treatment of COVID-19. Ivermectin is not registered in SA as a drug for human use, but rather as a veterinary and agricultural product. Currently, from a small number of randomised controlled trials (RCTs), there does seem to be a signal of evidence for the use of ivermectin in the management of COVID-19. Pharmacists must, however, remain cognisant of their ethical responsibilities as well as the applicable regulations that prohibit the procurement and dispensing of any unregistered medicine. | en_US |
dc.description.department | Pharmacology | en_US |
dc.description.uri | https://medpharm.co.za/about-our-journals/sagp | en_US |
dc.identifier.citation | Schellack, N., Padayachee, N., Schellac, G. 2021, 'Ivermectin in the treatment of COVID-19— friend or foe?', South African General Practitioner, vol. 88, no. 1, pp. 11-14. | en_US |
dc.identifier.issn | 2706-9613 (print) | |
dc.identifier.issn | 2706-9621 (online) | |
dc.identifier.uri | https://repository.up.ac.za/handle/2263/87647 | |
dc.language.iso | en | en_US |
dc.publisher | Medpharm publications | en_US |
dc.rights | © 2021 The Author(s). Open Access article distributed under the terms of the Creative Commons License [CC BY-NC-ND 4.0]. | en_US |
dc.subject | Avermectin | en_US |
dc.subject | Ivermectin | en_US |
dc.subject | Macrocyclic lactone | en_US |
dc.subject | Endectocide | en_US |
dc.subject | Coronavirus disease 2019 (COVID-19) | en_US |
dc.subject | COVID-19 pandemic | en_US |
dc.subject | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) | en_US |
dc.title | Ivermectin in the treatment of COVID-19-friend or foe? | en_US |
dc.type | Article | en_US |